Circle Cardiovascular Imaging vs Heartflow
The deepest evidence base in the category against the only on premise architecture in it. Heartflow computes physiology: FFRCT estimates lesion significance, supported by the ACC AHA Chest Pain Guideline, the recognition no competitor holds, on more than 600 publications and 400,000 plus patients, delivered as a cloud service that transmits every scan out for processing. Circle keeps imaging inside the institution: cvi42 Plaque runs fully on premise, the clearest data residency position in the lane and effectively the only option for buyers under sovereignty constraints, on a scanner agnostic reading platform a clinician drives directly. The two barely compete on the same axis, Heartflow wins decisively on evidence and guideline status, Circle wins decisively on architecture and data control, and neither closes the other's gap. Circle also grades C on evidence, since no validation study specific to cvi42 Plaque was located, against Heartflow's A. If your failure mode is guideline backed physiology with the deepest evidence behind it, start with Heartflow. If your failure mode is imaging that cannot leave the enterprise, start with Circle.
- The strongest data residency position in the lane: cvi42 Plaque runs fully on premise, so imaging never leaves the institution, graded A on PHI stewardship and deployment, where Heartflow transmits every scan to vendor side processing.
- Scanner agnostic by heritage: cvi42 is a multi vendor cardiovascular reading platform compatible with all major systems, graded A on interoperability, spanning cardiac MRI and CT rather than a single disease pathway.
- Direct clinician control on premise: a Johns Hopkins user describes immediate and interactive control over the analysis, the counterpoint to a send out service with vendor side quality control of undisclosed extent.
- The recognition no one else holds: FFRCT is supported by the ACC AHA Chest Pain Guideline, a materially higher bar than a 510(k), graded A on regulatory status against Circle's single module B.
- Evidence depth without rival: more than 600 peer reviewed publications and clinical use across 400,000 plus patients, an A on clinical evidence, where no validation study specific to cvi42 Plaque was located and Circle grades C.
- Physiology plus the full pathway: FFRCT for lesion significance alongside plaque, stenosis detection, and intervention planning under one platform in cleared markets, a broader clinical span than plaque quantification alone.
Side-by-Side
| Axis | C Circle Cardiovascular Imaging |
H Heartflow |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
The two strongest strengths in this pairing sit on opposite vendors and rarely trade off directly. Heartflow holds A on regulatory status for ACC AHA guideline recognition of FFRCT and A on clinical evidence for the largest base in the index, but its Plaque and RoadMap functions are cleared in only five countries, and it transmits imaging out for processing whose human step is undisclosed. Circle holds A on PHI stewardship, deployment, and interoperability for fully on premise, scanner agnostic analysis, but grades B on AI centrality as a platform with a plaque module and C on clinical evidence, since no validation study specific to cvi42 Plaque was located. Heartflow's own dossier candidly describes FFRCT reimbursement as inadequate, a disclosure this index credits. Neither publishes a licence price; Circle's on premise model resolves data residency structurally where Heartflow's terms are undisclosed.